Sacubitril/valsartan significantly reduced cardiomyopathy risk by 77% in patients on anthracycline chemotherapy compared to placebo. The SARAH trial highlights the need to identify high-risk patients ...
Association of sodium-glucose co-transporter-2 inhibitors with cardiac outcomes and mortality in cancer patients: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the 2025 ...
Examining the risk factors for trastuzumab-related cardiotoxicity in a predominantly Hispanic South Texas population: A descriptive study. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results